Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Tempo Therapeutics Inc
Profile last edited on: 12/5/2017      CAGE: 799L6      UEI: EA4HW67GFBS1

Business Identifier: Inject-able hydro gels for tissue regeneration
Year Founded
2014
First Award
2016
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1827 Veteran Avenue Suite 4
Los Angeles, CA 90025
   N/A
   info@tempothera.com
   www.tempothera.com
Location: Single
Congr. District: 36
County: Los Angeles

Public Profile

Using fully synthetic materials that do not require stem cell or biologic delivery, Tempo Therapeutics is working on development of micro porous gel for cutaneous-tissue regeneration and tissue-structure formation at the site of a wound and helps in preventing scarring.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
2
Conversion Rate
50.00%
Phase I Dollars
$1,218,051
Phase II Dollars
$3,411,095
Total Awarded
$4,629,146

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NSF $1,255,998
Project Title: A new vaccine technology to engineer a potent and polarized immunity against COVID-19
2022 2 NIH $2,549,497
Project Title: A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients
2020 2 NIH $1,598,652
Project Title: MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds
2016 1 NIH $224,999
Project Title: A Flowable Microporous Biomaterial as a Low Cost, High Efficacy Diabetic Chronic Ulcer Treatment

Key People / Management

  Westbrook M Weaver -- Founder and CEO

  Stephanie Deshayes

Company News

There are no news available.